JOP20210169B1 - أجسام مضادة أحادية النسيلة ضد منطقة سلسلة بيتا من trbv9 بشري - Google Patents

أجسام مضادة أحادية النسيلة ضد منطقة سلسلة بيتا من trbv9 بشري

Info

Publication number
JOP20210169B1
JOP20210169B1 JOJO/P/2021/0169A JOP20210169A JOP20210169B1 JO P20210169 B1 JOP20210169 B1 JO P20210169B1 JO P20210169 A JOP20210169 A JO P20210169A JO P20210169 B1 JOP20210169 B1 JO P20210169B1
Authority
JO
Jordan
Prior art keywords
antibody
human
trbv9
beta
monoclonal antibodies
Prior art date
Application number
JOJO/P/2021/0169A
Other languages
Arabic (ar)
English (en)
Inventor
Dmitry Valentinovich Morozov
Arina Vitalevna Anikina
Anna Valentinovna Evstrateva
Roman Alekseevich Ivanov
Pavel Andreevich Iakovlev
Olga Vladimirovna Britanova
Dmitry Borisovich Staroverov
Mariia Aleksandrovna Shchemeleva
Anna Konstantinovna Vladimirova
Sergey Anatolievich Lukyanov
Alexey Konstantinovich Misorin
Timofey Aleksandrovich Nemankin
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of JOP20210169A1 publication Critical patent/JOP20210169A1/ar
Application granted granted Critical
Publication of JOP20210169B1 publication Critical patent/JOP20210169B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JOJO/P/2021/0169A 2018-12-25 2021-06-24 أجسام مضادة أحادية النسيلة ضد منطقة سلسلة بيتا من trbv9 بشري JOP20210169B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2018146031A RU2712251C1 (ru) 2018-12-25 2018-12-25 Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
PCT/RU2020/050024 WO2020139175A2 (ru) 2018-12-25 2020-02-20 Гуманизированные антитела против участка бета цепи 9-го семейства trbv9 ткр человека, и способы их применения

Publications (2)

Publication Number Publication Date
JOP20210169A1 JOP20210169A1 (ar) 2023-01-30
JOP20210169B1 true JOP20210169B1 (ar) 2025-10-01

Family

ID=69184123

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2021/0169A JOP20210169B1 (ar) 2018-12-25 2021-06-24 أجسام مضادة أحادية النسيلة ضد منطقة سلسلة بيتا من trbv9 بشري

Country Status (26)

Country Link
US (1) US12227572B2 (cg-RX-API-DMAC7.html)
EP (1) EP3907239A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022532274A (cg-RX-API-DMAC7.html)
KR (2) KR102788029B1 (cg-RX-API-DMAC7.html)
CN (2) CN113646333B (cg-RX-API-DMAC7.html)
AR (1) AR117734A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020204492B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012555A2 (cg-RX-API-DMAC7.html)
CA (2) CA3127767A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001705A1 (cg-RX-API-DMAC7.html)
CO (2) CO2021008218A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210354A (cg-RX-API-DMAC7.html)
EA (1) EA202191813A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP21046333A (cg-RX-API-DMAC7.html)
IL (1) IL284370A (cg-RX-API-DMAC7.html)
JO (1) JOP20210169B1 (cg-RX-API-DMAC7.html)
MA (1) MA53689B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021007719A (cg-RX-API-DMAC7.html)
MY (1) MY205967A (cg-RX-API-DMAC7.html)
PE (1) PE20220217A1 (cg-RX-API-DMAC7.html)
PH (2) PH12021551775A1 (cg-RX-API-DMAC7.html)
RU (1) RU2712251C1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106975VA (cg-RX-API-DMAC7.html)
TW (1) TWI917314B (cg-RX-API-DMAC7.html)
WO (2) WO2020091635A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104357B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2694412C9 (ru) 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
RU2712251C1 (ru) * 2018-12-25 2020-01-27 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス,インコーポレーテッド NKp30に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN116867519A (zh) * 2020-12-01 2023-10-10 约翰斯霍普金斯大学 治疗t细胞癌症的方法和材料
CN116510006A (zh) * 2022-01-31 2023-08-01 拜奥卡德联合股份公司 抗trbv9抗体的药物组合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766947A (en) 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
CA2765949C (en) * 2009-06-25 2016-03-29 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
EP3202784A1 (en) * 2016-02-08 2017-08-09 Polybiocept AB T-cell receptor sequences for active immunotherapy
RU2694412C9 (ru) 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения
RU2712251C1 (ru) * 2018-12-25 2020-01-27 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения

Also Published As

Publication number Publication date
EP3907239A2 (en) 2021-11-10
KR102788029B1 (ko) 2025-03-31
CO2021009689A2 (es) 2021-08-09
CN113646333A (zh) 2021-11-12
EP3907239A4 (en) 2022-10-05
KR20210119404A (ko) 2021-10-05
IL284370A (en) 2021-08-31
JOP20210169A1 (ar) 2023-01-30
ZA202104357B (en) 2022-09-28
TWI917314B (zh) 2026-03-11
BR112021012555A2 (pt) 2021-09-14
WO2020139175A2 (ru) 2020-07-02
CN113646333B (zh) 2025-04-08
PH12021551775A1 (en) 2022-05-23
WO2020139175A3 (ru) 2020-10-29
EA202191813A1 (ru) 2021-10-07
WO2020091635A2 (ru) 2020-05-07
CO2021008218A2 (es) 2021-07-30
JP2022532274A (ja) 2022-07-14
CL2021001705A1 (es) 2022-01-28
US20220112286A1 (en) 2022-04-14
CA3127767A1 (en) 2020-05-07
PE20220217A1 (es) 2022-02-02
RU2712251C1 (ru) 2020-01-27
TW202039574A (zh) 2020-11-01
MA53689A1 (fr) 2022-06-30
MA53689B1 (fr) 2023-03-31
SG11202106975VA (en) 2021-07-29
CN114144432A (zh) 2022-03-04
US12227572B2 (en) 2025-02-18
MX2021007719A (es) 2022-03-25
AR117734A1 (es) 2021-08-25
ECSP21046333A (es) 2021-07-30
CA3124813A1 (en) 2020-07-02
WO2020091635A3 (ru) 2020-10-22
MY205967A (en) 2024-11-21
AU2020204492B2 (en) 2026-07-30
PH12021551532A1 (en) 2022-02-28
KR20220131489A (ko) 2022-09-28
CR20210354A (es) 2021-12-20
AU2020204492A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
JOP20210168B1 (ar) أجسام مضادة أحادية النسيلة ترتبط نوعيًا مع trbv9 بشري
MY205967A (en) Monoclonal antibodies against the beta chain region of human trbv9
EA202091569A1 (ru) Моноклональные антитела и способы их применения
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
EA201590208A1 (ru) Усиление активности т-клеток car путем совместного введения биспецифического антитела
EA033072B1 (ru) Применение антител к семафорину 4d для лечения болезни хантингтона
UA114108C2 (uk) Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
JP2017508475A5 (cg-RX-API-DMAC7.html)
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
EA201391453A1 (ru) Новое антитело против рецептора il-23 человека
MY202687A (en) Pharmaceutical chimeric receptor composition and method thereof
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения
MX2017010306A (es) Bloqueadores del receptor de la hormona del crecimiento en la prevencion y tratamiento de enfermedades.
ECSP19018367A (es) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
EA202092588A1 (ru) Клетки-естественные киллеры, сконструированные для экспрессии химерных антигенных рецепторов с блокадой иммунных контрольных точек
EA202092497A1 (ru) Анти-cd27 и анти-pd-l1 антитела и биспецифические конструкции